DUBLIN–(BUSINESS WIRE)–The “Understanding Active Pharmaceutical Ingredients (APIs) Training Course (Apr 29th – Apr 30th, 2026)” training has been added to ResearchAndMarketsDUBLIN–(BUSINESS WIRE)–The “Understanding Active Pharmaceutical Ingredients (APIs) Training Course (Apr 29th – Apr 30th, 2026)” training has been added to ResearchAndMarkets

Understanding Active Pharmaceutical Ingredients (APIs): Online Training Course (Apr 29-30, 2026) – Enhance Your API Expertise with In-Depth GMP and GDP Training – ResearchAndMarkets.com

2026/01/22 03:32
3 min read

DUBLIN–(BUSINESS WIRE)–The “Understanding Active Pharmaceutical Ingredients (APIs) Training Course (Apr 29th – Apr 30th, 2026)” training has been added to ResearchAndMarkets.com’s offering.

An active pharmaceutical ingredient (API) or drug substance is any substance or mixture of substances intended to be used in the manufacture of a medicinal product, which is intended to furnish pharmacological activity, or have another direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or affect the structure and function of the body.

This course has been designed to provide attendees with a fundamental understanding of best practice and the regulatory environment applicable to active pharmaceutical ingredients in the pharmaceutical industry. It will cover key terminology, the EU and USA regulatory framework, Good Manufacturing Practice (GMP) requirements including controls and validation, and consider Good Distribution Practice (GDP) and how to manage your supply chain. Practical exercises will form part of the course to aid the learning process.

This is an essential and valuable introduction to the manufacture of APIs.

Benefits of Attending:

  • Gain a comprehensive overview of the API regulatory framework
  • Enhance your understanding of the key terms used in API manufacture
  • Recognise how Good Manufacturing Practices (GMP) apply to API synthesis
  • Understand the different approaches between small-molecule and large molecule processing
  • Learn how to manage the risk associated with your supply chain

Who Should Attend:

  • New entrants to those individuals working in a GxP environment
  • Quality management manufacturing specialists
  • Regulatory compliance specialists
  • Pharmaceutical technical professionals
  • Pharmaceutical professionals looking to enhance their Continuous Professional Development (CPD)

Agenda: Day 1

Introduction to APIs

  • Terminology and acronyms
  • Globalisation
  • Introduction to the regulatory framework

Methods and equipment – Part 1

  • Chemical synthesis
  • Reactors
  • Isolation
  • Drying
  • Exercise: managing particle size

Methods and equipment – Part 2

  • Biological
  • Fermentation
  • Harvesting
  • Exercise: impurities

Good Manufacturing Practice (GMP)

  • Requirements
  • Regulations
  • EU
  • FDA
  • Exercise: similarities and differences

GMP requirements (continued)

  • Pharmaceutical Quality System
  • Validation and Qualification
  • Outsourcing
  • Exercise: specialist or generalist

Supply chain considerations

  • Falsified Medicines Directive (FMD)
  • Good Distribution Practice (GDP) for APIs
  • Exercise risk mitigation

Agenda: Day 2

Introduction and recap

Registration aspects of production and control

  • The registration process
  • The Common Technical Document (CTD)
  • Active substance/drug master files
  • Exercise: strategy

Laboratory controls

  • Good Quality Control Laboratory Practice (GQCLP)
  • Validation
  • Stability
  • Exercise: data Integrity

Process validation

  • Purpose of validation
  • General considerations
  • Exercise: critical attributes

Cleaning validation

  • Cleaning strategy
  • Key requirements
  • Residues
  • Exercise: purpose

API control packaging materials

  • What to consider
  • Data requirements
  • Extraction, interaction, migration and sorption
  • Toxicology
  • Exercise: environmental factors

Wrap up and Q&A

For more information about this training visit https://www.researchandmarkets.com/r/ydcok1

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Market Opportunity
aPriori Logo
aPriori Price(APR)
$0.08786
$0.08786$0.08786
+6.54%
USD
aPriori (APR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26